Managers Jonathan Coleman, Scott Stutzman, and Aaron Schaechterle search for competitively advantaged businesses that can grow throughout the economic cycle. Valuation is an important consideration.

DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume ...

Dexcom (Nasdaq:DXCM) has a new chief commercial officer with significant experience at another major medtech company.

This innovation, along with the appointment of Jon Coleman as the Chief Commercial Officer, potentially bolstered investor confidence. Meanwhile, broader market trends showed a slight decline in ...

SAN DIEGO, March 25, 2025--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer.

DexCom (DXCM) announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for ...

SAN DIEGO, March 25, 2025--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this ...

The appointment of Jon Coleman as chief commercial officer is based on a press release statement from DexCom, Inc. In other recent news, DexCom reported fourth-quarter earnings with adjusted ...

SAN DIEGO - DexCom, Inc. (NASDAQ: DXCM), a prominent player in glucose biosensing technology with a market capitalization of $28.75 billion and an "GREAT" financial health rating according to ...